Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Cheyne, Leanne ^a   Irvin Sellers, Melanie J ^b   White, John ^c  

^a BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST PETER S HOSPITAL   (United Kingdom)

^c YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SCOPOLAMINE DERIVATIVE;

ADULT; BASELINE DYSPNEA INDEX; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE ASSESSMENT; REVIEW; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITION DYSPNEA INDEX; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; META ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

BRONCHODILATOR AGENTS; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE;

EID: 84898753680     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009552.pub2     Document Type: Review

References (36)

1. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. European Respiratory Journal 2004;23(2):241-9.
2. Van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJG. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55(4):289-94.
3. Vincken W, van Noord JA, Greefhorst A, Bantje TA, Kesten S, Korducki L, et al.Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. European Respiratory Journal 2002;19(2):209-16.
4. Clinical trial 205.251. Boehringer Ingelheim.
5. Clinical trial 205.252. Boehringer Ingelheim.
6. Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, et al.A randomized study of tiotropium Respimats Soft MistTM Inhaler vs. ipratropium pMDI in COPD. Respiratory Medicine 2008;102:32-41.
7. Kim SJ, Kim MS, Lee SH, Kim YK, Moon HS, Park SH, et al.A comparison of tiotropium 18mug, once daily and ipratropium 40mug, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease. Tuberculosis and Respiratory Diseases 2005;58(5):498-506.
8. Niewoehner DE, Lapidus R, Cote C, Sharafkhaneh A, Plautz M, Johnson P, et al.Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics 2009;22(6):587-92.
9. Serby CW, Schwartzstein RM, Jones PW, Ries AL, Killian KJ. Tiotropium: 1-Yr studies versus placebo/ipratropium. European Respiratory Review 2002;12(82):40-2.
10. Wang HY, Xiao Y, Shi LL, Gong Q, Wen ZG. Study on efficacy and safety of tiotropium powder in patients with stable COPD. Chinese Journal of New Drugs 2007;16(14):1119-22.
11. Zheng JP, Kang J, Cai BQ, Zhou X, Cao ZL, Bai CX, et al.Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease. Chinese Journal of Tuberculosis and Respiratory Diseases 2006;29(6):363-7.
12. Barnes P. The pharmacological properties of tiotropium. Chest 2000;117:63S.
13. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2005, issue 2. [DOI: 10.1002/14651858.CD002876.pub2]
14. British National Formulary. www.bnf.org (accessed 1 November 2011).
15. Cates CJ. Safety of tiotropium. BMJ June 2011;14:342.
16. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1):20-30.
17. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68(1):48-56.
18. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD 2010.
19. Healthcare Commission. Clearing the air: A national study of chronic obstructive pulmonary disease. Healthcare Commission 2006.
20. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, Available from www.cochrane-handbook.org, 2008.
21. Karner C, Cates CJ. The added effect of inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD009039]
22. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2]
23. Karner C, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008989]
24. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD009285.pub2]
25. ® in the treatment of COPD: A safety review. International Journal of Chronic Obstructive Pulmonary Disease 2009;4:397-409.
26. Lubinski W. Tiotropium as a controller of bronchoconstriction. Polski Merkuriusz Lekarski 2004;16:75-76, 78.
27. NICE. Chronic Obstructive Pulmonary Disease: full guideline. NICE guidelines June 2010.
28. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010; Vol. 137, issue 1:13-9. [0012-3692]
29. Ram FS. Tiotropium mist inhaler for COPD increases risk of mortality compared with placebo. Evidence Based Medicine 2011;16(6):189-90.
30. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
31. Salpeter R, Buckley N, Salpeter E. Meta-analysis: Anticholinergics, but not beta agonists, reduce severe exacerbations and respiratory mortality in COPD. Journal of General Internal Medicine 2006;21(10):1011-9.
32. Sears M, Hamilton M. Long-acting bronchodilators in COPD. Chest 2008;133(5):1057-8.
33. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(12):1439-50.
34. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013;68(1):114-6.
35. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2]
36. Yohannes AW, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: A meta-analysis of clinically relevant outcomes. Respiratory Care 2011;56(4):477-87.